The following information was received on (b)(6)2024, from the distributor.Lesion : ostial circumflex (moderate calcification) sufficient balloon prep was done with a 3.5 15 ryurei to 12 atm before attempting to cross lesion with an elunir 3.5 24 the elunir was observed not to be manoeuvring as per normal with the operator encountering difficulty passing the stent into the circumflex.Subsequently stent was retrieved and both the distal and proximal stent edges were observed to have been flared / disfigured.The stent was retrieved and will be sent back to medinol for investigation.An elunir 3.5 20 was used after further pre dilation with the 3.5 ryurei and this time it passed into the lesion.Patient is stable.Additional information was received from the distributor on (b)(6) 2024 the following was mentioned: 1.The event caused a significant prolongation of patient hospitalization, but the explanation for the prolongation couldn't be provided.2.The physician couldn't maneuver the system normally and failed to passing the stent into the circumflex.3.No anomalies noted during the device unpackaging.4.The device was prepared normally.5.No resistance/unusaul (abnormal) friction was noticed by the physician, while inserting the balloon through the guide wire.6.No kink of the stent delivery system was noticed during the use by the physician.7.No kinks/bends/damage were exhibited on the guide catheter/guide wire during use.8.The procedural angiogram of the process is not available.Dhr review - (b)(6) 2024 all systems, including stent compliance, were 100% visually inspected at final visual inspection station.The systems successfully passed the release test.
|
Following the device arrival, a device analysis was signed om 21 april 2024 (see enclosed).On 21 april 2024, a review of ifu for customer complaint was performed, no deviation was reported.Final complaint report, signed on 06 may 2024, revealed the following conclusions: a.The review of dhr (device history record) of lot # lnrin0770b indicated that the rpoduct ws supplied meeting the specifications.B.The result of the investigation indicate that the returned product was supplied to the customer meeting specifications.Failure to cross is usually the cosequence of one or a combination of the common issues such as patient anatomy, lesion disposition/composition, operator technique, ancillary equipmentand/or appropriate device selection.No relation was found to medinol's manufacturing process.C.The event of this complaint is addressed in the elunir dfmea report, and the risk remains low.No new risks were identified.D.There was no injury to the patient.
|